Greenland Mines Ltd. (GRML) Next Earnings Date & Expected ±12.5% Move

$4.58 -10.89% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.48

Greenland Mines Ltd. (GRML) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $70.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GRML Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GRML stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Greenland Mines Ltd. (NASDAQ: GRML) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.58 (-10.89% 1D, market cap $70.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GRML ranks #780 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GRML compare to CGTX and CRDF in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GRML carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CGTX (Cognition Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and CRDF (Cardiff Oncology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M). Among the 5-stock peer group, GRML leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GRML?
▼

Per GRML's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001907223), Greenland Mines Ltd. generated $0 in revenue, -$10.6M in net income, and -$5.9M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.48 (-2.15%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (6)Whales (5)SEC (10)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.8% Base Target
$39 Bull$4 Base$3 Bear
📬 FREE GRML RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRML)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY GRML SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (25% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 39 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$5.17+16.1% Next Q
Q2 (-2Q)
37
Grade E$6.00-3.7% Next Q
Q3 (-1Q)
35
Grade E$5.78-20.8% Next Q
Current
32
Grade E$4.58-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GRML Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GRML currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.60) and Max Pain ($4.81) forces dealer call-delta covering toward $38.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GRML• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GRML Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.57 Expected Swing
$4.01 (-12.5%)Spot $4.58$5.15 (+12.5%)
MODEL EARNINGS SETUP GAUGE

GRML Quantitative Pre-Earnings Setup: 32/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (32/100)Model Risk Weight (68/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$0-$10.6M-$5.9M52%
FY 20242024-12-31$0-$6.2M-$2.9M52%
FY 20232023-12-31$0-$707.5K-$446.9K52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRML)

  • ✓Walkthrough of GRML's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GRML // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.00%📐 HORIZONTAL RANGE
2026-10-30O $5.00H $5.00L $4.35C $4.58VOL 1.36M
RES: $18.74SUP: $-0.50SMA50: $6.60SMA200: $13.74
$29.23$22.07$14.91$7.76$0.60RES $18.74SUP $-0.50$4.582026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRML Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GRML today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRML. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GRML today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRML)

Health Care Rank #780 of 1016 ⚔️ CGTX vs GRML Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GRML vs. CGTX, CRDF, NMRA, CSBR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Greenland Mines Ltd. (GRML) ranks #780 by composite RQD confidence (32/100, grade E) and #706 by equity capitalization ($70.3M). Within this direct 5-issuer industry benchmark cohort, GRML leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with GRML at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GRML ACTIVE
Greenland Mines Ltd.
E 32/100 — — -35.0% -10.89% $70.3M Benchmark Subject
CGTX
Cognition Therapeutics Inc.
D- 43/100 — — -35.0% -5.57% $70.3M /cgtx-vs-grml →
CRDF
Cardiff Oncology Inc.
D- 41/100 — — -35.0% -2.46% $70.9M /crdf-vs-grml →
NMRA
Neumora Therapeutics Inc.
D- 42/100 — — -35.0% -5.43% $73.0M /nmra-vs-grml →
CSBR
Champions Oncology Inc.
E 22/100 — 48.0% -26.9% 0.00% $66.9M /csbr-vs-grml →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001907223

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Greenland Mines Ltd. (GRML) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.6M, operating cash flow of -$5.9M, and free cash flow of -$5.9M (-99.9% YoY). On the balance sheet, GRML closed FY2025 with $9.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$10.6M -$5.9M -$5.9M $9.6M —
FY2024 (FY) 2024-12-31 $0 -$6.2M -$2.9M -$2.9M $2.5M —
FY2023 (FY) 2023-12-31 $0 -$707.5K -$446.9K -$446.9K — —

3. GRML Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRML stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Greenland Mines Ltd. (NASDAQ: GRML) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.58 (-10.89% 1D, market cap $70.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GRML ranks #780 in composite RQD confidence.

How does GRML compare to CGTX and CRDF in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GRML carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CGTX (Cognition Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and CRDF (Cardiff Oncology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M). Among the 5-stock peer group, GRML leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GRML?

Per GRML's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001907223), Greenland Mines Ltd. generated $0 in revenue, -$10.6M in net income, and -$5.9M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GRML trading relative to its 50-day, 200-day, and 52-week technical levels?

GRML last traded at $4.58 (-10.89% on volume of 1,359,728 shares), positioning the stock -30.61% below its 50-day simple moving average ($6.60) and -66.67% below its 200-day simple moving average ($13.74). Across its 52-week range of $2.82 to $37.00, GRML sits at the 5.1% percentile with a 14-day RSI of 39.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.01 to $5.15).

GRML Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is GRML's next earnings date?

Based on SEC filing cadence, Greenland Mines Ltd. (GRML)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is GRML stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for GRML, spanning a range between $4.01 and $5.15.

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GRML — Greenland Mines Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:45:38Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating assigns GRML a score of 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars are:

  • Fundamental Cash Engine: 6 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and FCF yield of -8.37%. For a prospective investor, the company is currently destroying capital and not generating free cash flow relative to its market value, which removes the most durable source of intrinsic support.
  • Whale 13F Flow: 5 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is low, indicating limited evidence of sustained institutional conviction in the source data.
  • Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. It is the lowest pillar score, meaning the signal from insider and congressional activity does not support the thesis.
  • Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. Market-level exposure is neutral by beta, but the score indicates weak alignment with the current macro regime.
  • Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. The Piotroski reading is weak, and the score reflects forensic caution despite a moderate Altman Z.

Taken together, the pillars point to a stock where the cash engine, insider signal, and forensic quality all score in the weak range. Upside would depend on a reversal in cash generation, which the current data does not show. Valuation tradeoffs are difficult to assess because P/E and EV/EBITDA are not available in source data, and the 52-week range of $2.82 to $37 illustrates very high volatility relative to the current $4.58 price.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-7.1M$-10.6MN/A$-5.9M$7.2MN/A
FY 2024$0.0M$-5.5M$-6.2MN/A$-2.9M$0.1MN/A
FY 2023$0.0M$-0.6M$-0.7MN/A$-0.4MN/AN/A

Per the SEC financials, reported losses widened across the three periods, with net income moving from $-0.7M to $-10.6M and free cash flow from $-0.4M to $-5.9M. Gross, operating, and net margins are each 0% per the market data, consistent with zero reported revenue. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2/9. Debt/Equity is 0.5 per the Roarable RQD rating, while debt in the SEC financials is Not available in source data for each period; the balance-sheet posture therefore rests on cash of $7.2M at FY 2025 against the company's negative cash flows.

Open Questions

  • What products, customers, or development programs generate or are expected to generate revenue, given zero reported revenue in each period?
  • What are the debt obligations behind the Debt/Equity of 0.5, since debt is not reported in the SEC financials?
  • How much of the $59 million raised is already reflected in the FY 2025 cash of $7.2M, and what is the dilution impact on share count?
  • Is the $20M buyback funded from existing cash, and how does it reconcile with negative free cash flow of $-5.9M?
  • What is the reason for the 52-week range of $2.82 to $37, and what drove the current $4.58 price?

GRML Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Greenland Mines Ltd. (GRML) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GRML Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GRML Bull vs. Bear Conversation Board — What's Your Call at $4.58?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GRML 🐻 67% BEARISH CONVICTION
1. Pick Your Side on GRML:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.03 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GRML (E • RQD 32/100) a Buy at $4.58?

Welcome to the GRML (Greenland Mines Ltd.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.48 (-24.0%)
Spot @ $4.58

Pump the brakes on GRML — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GRML, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Greenland Mines Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $5.82 (+27.1%)
Spot @ $4.58

GRML cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GRML, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $4.58 (52-wk range $2.82 - $37.00), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%